US FDA recommends temporary suspension of GlaxoSmithKline's Rotarix due to extraneous virus
Vaccine news was at the forefront late yesterday, after the US Food and Drug Administration found problems with UK drug major GlaxoSmithKline's Rotarix, which generated some £282 million ($423.5 million) of sales for the firm in 2009, up 50% on the previous year, £76 million of which came from the USA. The news had no impact on GSK's share price, which edged 0.6% higher to £12.86 by close of London trading yesterday.
The FDA is recommending that health care practitioners temporarily suspend use of the Rotarix vaccine for rotavirus immunization in the USA while the agency learns more about components of an extraneous virus detected in the vaccine, though stressing that there is no evidence at this time that this finding poses a safety risk.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze